BR9913696A - Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial - Google Patents
Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacialInfo
- Publication number
- BR9913696A BR9913696A BR9913696-1A BR9913696A BR9913696A BR 9913696 A BR9913696 A BR 9913696A BR 9913696 A BR9913696 A BR 9913696A BR 9913696 A BR9913696 A BR 9913696A
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- temporal
- spatial control
- control
- administered orally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<B>"SISTEMA DE LIBERAçãO DE DROGAS, ADMINISTRADO ORALMENTE, PROPORCIONANDO CONTROLE TEMPORAL E ESPACIAL"<D>. A presente invenção se refere a uma composição farmacêutica, na forma de comprimidos ou cápsulas, que proporciona uma combinação de controle temporal e espacial de liberação de droga a um paciente, para obtenção de efetivos resultados terapêuticos. A composição farmacêutica compreende uma droga, um componente gerador de gás, um agente de expansão, um agente promotor de viscosidade e, opcionalmente, um polímero formador de gel. O agente de expansão pertence à classe dos compostos conhecidos como super-desintegradores (por exemplo, polivinilpirrolidona reticulada ou carbóximetilcelulose de sódio). No início, o agente promotor de viscosidade e depois, o polímero formador de gel, formam uma matriz de gel hidratada que atrai o gás, fazendo flutuar o comprimido ou cápsula, de modo que os mesmos são retidos no estómago ou partes superiores do intestino delgado (controle espacial). Ao mesmo tempo, a matriz de gel hidratada cria um percurso de difusão tortuoso para a droga, resultando numa liberação constante da droga (controle temporal). Uma formulação de ciprofloxacina preferida de administração diária, compreende 69,9% de uma base de ciprofloxacina, 0,34% de alginato de sódio, 1,03% de goma de xantan, 13,7% de bicarbonato de sódio, 12,1% de polivinilpirrolidona reticulada e, opcionalmente, outros excipientes farmacêuticos, a formulação sendo na forma de um comprimido ou cápsula revestido ou não revestido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/152,932 US6261601B1 (en) | 1997-09-19 | 1998-09-14 | Orally administered controlled drug delivery system providing temporal and spatial control |
| PCT/IB1999/000078 WO2000015198A1 (en) | 1998-09-14 | 1999-01-19 | Orally administered controlled drug delivery system providing temporal and spatial control |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9913696A true BR9913696A (pt) | 2001-10-09 |
Family
ID=22545063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9913696-1A BR9913696A (pt) | 1998-09-14 | 1999-01-19 | Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial |
Country Status (41)
| Country | Link |
|---|---|
| EP (2) | EP1107741B1 (pt) |
| JP (1) | JP2002524494A (pt) |
| CN (1) | CN1186013C (pt) |
| AP (1) | AP1659A (pt) |
| AR (1) | AR022672A1 (pt) |
| AT (1) | ATE245414T1 (pt) |
| AU (1) | AU758324B2 (pt) |
| BG (1) | BG105339A (pt) |
| BR (1) | BR9913696A (pt) |
| CA (1) | CA2343760A1 (pt) |
| CO (1) | CO5130022A1 (pt) |
| CU (1) | CU23040A3 (pt) |
| CZ (1) | CZ2001901A3 (pt) |
| DE (1) | DE69909801T2 (pt) |
| DK (1) | DK1107741T3 (pt) |
| EA (2) | EA004443B1 (pt) |
| EE (1) | EE200100153A (pt) |
| ES (1) | ES2204098T3 (pt) |
| GE (1) | GEP20043216B (pt) |
| HK (1) | HK1037967A1 (pt) |
| HR (1) | HRP20010187B1 (pt) |
| HU (1) | HUP0103632A3 (pt) |
| ID (1) | ID29843A (pt) |
| IL (1) | IL141977A0 (pt) |
| IS (1) | IS5885A (pt) |
| MX (1) | MXPA01002634A (pt) |
| MY (1) | MY127952A (pt) |
| NO (1) | NO20011276L (pt) |
| NZ (2) | NZ510487A (pt) |
| OA (1) | OA11652A (pt) |
| PE (1) | PE20001058A1 (pt) |
| PL (1) | PL346798A1 (pt) |
| PT (1) | PT1107741E (pt) |
| SI (1) | SI1107741T1 (pt) |
| SK (1) | SK285478B6 (pt) |
| SV (1) | SV1999000152A (pt) |
| TR (1) | TR200100731T2 (pt) |
| UA (1) | UA73287C2 (pt) |
| UY (1) | UY25710A1 (pt) |
| WO (1) | WO2000015198A1 (pt) |
| ZA (1) | ZA995839B (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2400950A1 (en) * | 2000-03-03 | 2001-09-07 | Ranbaxy Laboratories Limited | Orally administered controlled delivery system for once daily administration of ciprofloxacin |
| DE10031043A1 (de) | 2000-06-26 | 2002-02-14 | Bayer Ag | Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung |
| AU2006202275A1 (en) * | 2000-06-26 | 2006-06-22 | Bayer Healthcare Ag | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| JP3573287B2 (ja) | 2000-08-08 | 2004-10-06 | 第一製薬株式会社 | 高吸収性固形製剤 |
| IN192748B (pt) * | 2000-08-29 | 2004-05-15 | Ranbaxy Lab Ltd | |
| EP1347748A2 (en) | 2000-12-05 | 2003-10-01 | MacGregor, Alexander | Hydrostatic delivery system for controlled delivery of agent |
| WO2003011255A1 (en) | 2001-07-04 | 2003-02-13 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
| NZ531461A (en) * | 2001-08-16 | 2008-03-28 | Oregon State | Expandable gastric retention device |
| WO2003017981A1 (en) * | 2001-08-29 | 2003-03-06 | Ranbaxy Laboratories Limited | Controlled release formulation of clarithromycin or tinidazol |
| EP1439820A2 (en) * | 2001-10-29 | 2004-07-28 | Labopharm Inc. | Methods and dosage forms for improving the bioavailability of therapeutic agents |
| MXPA04004544A (es) * | 2001-11-13 | 2005-03-31 | Yamanouchi Pharma Tech Inc | Sistema de liberacion prolongada para droga soluble. |
| DE60117712T2 (de) | 2001-11-19 | 2006-11-16 | Lupin Ltd., Mumbai | Pharmazeutische zusammensetzung für die kontrollierte freisetzung eines beta-lactam-antibiotikums |
| CZ20041117A3 (cs) * | 2002-04-23 | 2005-04-13 | Lupin Limited | Dlouhodobě působící kompozice zahrnující zidovudin a lamivudin |
| WO2005018613A1 (de) * | 2003-08-26 | 2005-03-03 | Mandapro Ag | Pellets für die orale applikation von pharmazeutischen wirkstoffen |
| DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
| GB0501810D0 (en) * | 2005-01-28 | 2005-03-09 | Pharmakodex Ltd | Chemotherapeutic formulations |
| US20090099154A1 (en) * | 2005-06-29 | 2009-04-16 | Panacea Biotec Ltd. | Pharmaceutical Sustained Release Compositions and Processes Thereof |
| ATE396710T1 (de) * | 2005-07-19 | 2008-06-15 | Ethypharm Sa | Gastroretentive zusammensetzungen und verfahren zur herstellung |
| GB0515492D0 (en) * | 2005-07-28 | 2005-08-31 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions,articles and methods |
| KR20080076382A (ko) * | 2007-02-15 | 2008-08-20 | (주)아모레퍼시픽 | 실로스타졸의 제어방출 제제 및 그 제조방법 |
| ZA200903854B (en) * | 2008-06-19 | 2011-02-23 | Univ Of The Witwatesrand Johannesburg | A gastroretentive pharmaceutical dosage form |
| KR20110042366A (ko) | 2008-08-18 | 2011-04-26 | 팀 아카데미 오브 파마슈티컬 사이언스 | 위장체류 약물 전달 시스템, 제작 방법 및 그것들의 사용 |
| WO2011125075A2 (en) | 2010-04-08 | 2011-10-13 | Fdc Limited | A novel gastroretentive delivery of macrolide |
| EP2415460A1 (de) * | 2010-08-03 | 2012-02-08 | ratiopharm GmbH | Orale Darreichungsform von Pregabalin |
| TWI705814B (zh) * | 2014-06-20 | 2020-10-01 | 美商梅琳塔有限責任公司 | 醫藥組成物及其用途 |
| CN106999429B (zh) | 2014-11-19 | 2020-09-18 | 杜邦营养美国有限公司 | 纳米悬浮剂制剂 |
| US10987311B2 (en) | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
| US10918597B2 (en) | 2017-06-16 | 2021-02-16 | Kashiv Specialty Pharmaceuticals, Llc | Gastroretentive dosage forms for sustained drug delivery |
| US10588863B2 (en) | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
| EP3609472B1 (en) | 2018-06-18 | 2020-12-30 | Kashiv Specialty Pharmaceuticals, LLC | Extended release compositions comprising pyridostigmine |
| JP7034343B2 (ja) | 2018-06-27 | 2022-03-11 | アムニール コンプレックス プロダクツ リサーチ エルエルシー | 自己調節性の浸透性胃保持性薬物送達システム |
| CN110448535A (zh) * | 2019-09-04 | 2019-11-15 | 湖南宇山玉月农业科技有限公司 | 一种裂褶菌素胃漂浮片 |
| CN111116794A (zh) * | 2019-12-20 | 2020-05-08 | 蚌埠市鑫晟新材料科技有限公司 | 一种中性造纸用聚合材料的制备方法 |
| CN115715765A (zh) * | 2021-08-24 | 2023-02-28 | 江苏万邦生化医药集团有限责任公司 | 一种悬浮片剂 |
| CN113768898A (zh) * | 2021-09-14 | 2021-12-10 | 江苏万邦生化医药集团有限责任公司 | 悬浮的胶囊片 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0798742B2 (ja) * | 1986-07-03 | 1995-10-25 | ゼリア新薬工業株式会社 | 徐放性製剤組成物 |
| US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
| JPH0624959A (ja) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
-
1999
- 1999-01-19 PL PL99346798A patent/PL346798A1/xx unknown
- 1999-01-19 ES ES99900106T patent/ES2204098T3/es not_active Expired - Lifetime
- 1999-01-19 JP JP2000569782A patent/JP2002524494A/ja active Pending
- 1999-01-19 TR TR2001/00731T patent/TR200100731T2/xx unknown
- 1999-01-19 AT AT99900106T patent/ATE245414T1/de not_active IP Right Cessation
- 1999-01-19 CA CA002343760A patent/CA2343760A1/en not_active Abandoned
- 1999-01-19 NZ NZ510487A patent/NZ510487A/xx unknown
- 1999-01-19 UA UA2001031727A patent/UA73287C2/uk unknown
- 1999-01-19 CN CNB998129887A patent/CN1186013C/zh not_active Expired - Fee Related
- 1999-01-19 DK DK99900106T patent/DK1107741T3/da active
- 1999-01-19 OA OA1200100064A patent/OA11652A/en unknown
- 1999-01-19 SK SK347-2001A patent/SK285478B6/sk unknown
- 1999-01-19 HU HU0103632A patent/HUP0103632A3/hu unknown
- 1999-01-19 PT PT99900106T patent/PT1107741E/pt unknown
- 1999-01-19 CZ CZ2001901A patent/CZ2001901A3/cs unknown
- 1999-01-19 EE EEP200100153A patent/EE200100153A/xx unknown
- 1999-01-19 GE GEAP19995796A patent/GEP20043216B/en unknown
- 1999-01-19 EA EA200100346A patent/EA004443B1/ru not_active IP Right Cessation
- 1999-01-19 EA EA200300847A patent/EA005767B1/ru not_active IP Right Cessation
- 1999-01-19 NZ NZ523747A patent/NZ523747A/en unknown
- 1999-01-19 WO PCT/IB1999/000078 patent/WO2000015198A1/en not_active Application Discontinuation
- 1999-01-19 AU AU17794/99A patent/AU758324B2/en not_active Ceased
- 1999-01-19 ID IDW20010594A patent/ID29843A/id unknown
- 1999-01-19 EP EP99900106A patent/EP1107741B1/en not_active Expired - Lifetime
- 1999-01-19 SI SI9930376T patent/SI1107741T1/xx unknown
- 1999-01-19 MX MXPA01002634A patent/MXPA01002634A/es not_active Application Discontinuation
- 1999-01-19 DE DE69909801T patent/DE69909801T2/de not_active Expired - Fee Related
- 1999-01-19 EP EP02023169A patent/EP1281397A1/en not_active Withdrawn
- 1999-01-19 BR BR9913696-1A patent/BR9913696A/pt not_active IP Right Cessation
- 1999-01-19 CU CU20010067A patent/CU23040A3/es unknown
- 1999-01-19 IL IL14197799A patent/IL141977A0/xx unknown
- 1999-01-19 AP APAP/P/2001/002098A patent/AP1659A/en active
- 1999-09-10 ZA ZA9905839A patent/ZA995839B/xx unknown
- 1999-09-13 SV SV1999000152A patent/SV1999000152A/es not_active Application Discontinuation
- 1999-09-13 PE PE1999000924A patent/PE20001058A1/es not_active Application Discontinuation
- 1999-09-13 MY MYPI99003949A patent/MY127952A/en unknown
- 1999-09-14 UY UY25710A patent/UY25710A1/es unknown
- 1999-09-14 CO CO99058020A patent/CO5130022A1/es unknown
- 1999-09-17 AR ARP990104682A patent/AR022672A1/es not_active Application Discontinuation
-
2001
- 2001-03-12 IS IS5885A patent/IS5885A/is unknown
- 2001-03-13 HR HR20010187A patent/HRP20010187B1/xx not_active IP Right Cessation
- 2001-03-13 BG BG105339A patent/BG105339A/xx unknown
- 2001-03-13 NO NO20011276A patent/NO20011276L/no unknown
- 2001-12-11 HK HK01108695A patent/HK1037967A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9913696A (pt) | Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial | |
| YU19501A (sh) | Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu | |
| KR100283709B1 (ko) | 안정한 서방성 경구 투여 조성물 | |
| US4695591A (en) | Controlled release dosage forms comprising hydroxypropylmethylcellulose | |
| US7674480B2 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
| AU2001268722B2 (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
| KR950007841A (ko) | 트라마돌 염을 함유하는 서방성 약물 제제 | |
| JP5026262B2 (ja) | 経口抗菌医薬組成物 | |
| SE453797B (sv) | Terapeutisk, solid enhetsdoseringsform med forlengt utlosningsmonster vars berarmaterial innehaller hydroxypropylmetylcellulosa med hog molekyler vikt | |
| IL143375A0 (en) | Sustained release matrix systems for highly soluble drugs | |
| BRPI0317682B1 (pt) | Composição farmacêutica de liberação modificada na forma de uma cápsula | |
| CZ294342B6 (cs) | Farmaceutická tableta pro orální podávání s regulovaným uvolňováním účinné složky | |
| EP1315478A2 (en) | Controlled release formulation of erythromycin or a derivative thereof | |
| BR0212155A (pt) | Composição farmacêutica | |
| JP2646170B2 (ja) | 徐放性塩酸オキシブチニン製剤 | |
| HN2001000038A (es) | Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina | |
| JP2006508134A (ja) | 医薬組成物 | |
| JP2776837B2 (ja) | 消化性潰瘍治療剤 | |
| ECSP993138A (es) | Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial | |
| JP4824224B2 (ja) | 糖衣製剤 | |
| RU2234915C2 (ru) | Твердая фармацевтическая композиция для перорального введения и способ ее получения | |
| KR20020063753A (ko) | 불용성 약물의 서방형 제제의 제조방법 | |
| WO2017090902A1 (ko) | 구강 지혈 및 상처 보호 필름 | |
| TH50543A3 (th) | ระบบการนำส่งยาที่ควบคุมได้สำหรับให้ทางปากซึ่งให้การควบคุมเกี่ยวกับเวลาและบริเวณ | |
| BRPI0419032B1 (pt) | composição farmacêutica de liberação prolongada de hidralazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA(S) 8 A, 9A E 10A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009. |